Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 14, 2009

Boehringer Ingelheim Receives EC Clearance for Once-Daily Version of Parkinson's Therapy

  • The European Commission has sanctioned Boehringer Ingelheim’s prolonged-release, once-daily version of its Parkinson’s disease (PD) drug called Mirapexin®/Sifrol® (pramipexole). It is indicated for the treatment of early and advanced idiopathic PD.

    The approval was based on the submission of clinical trial results showing that the new formulation can offer an efficacy and safety profile comparable to the immediate-release tablet, which is taken three times daily.

    An NDA for the once-daily, extended-release formulation of pramipexole is under review with the FDA.

     



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »